Mendelian susceptibility to mycobacterial diseases: An overview
- Gulbu Uzel, MD
Gulbu Uzel, MD
- Clinical Investigator
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Mendelian susceptibility to mycobacterial diseases (MSMD, MIM #209950) is caused by genetic defects in the mononuclear phagocyte/T helper cell type 1 (Th1) pathway . Even though the name MSMD implies infections with mycobacteria only, infections with other pathogens have been described with this disorder. Typically, patients with MSMD have increased susceptibility to systemic infections caused by pathogens with varying degrees of virulence, from weakly virulent environmental nontuberculous mycobacteria (NTM), to Bacillus Calmette-Guérin (BCG), to disseminated infection with Mycobacterium bovis or Mycobacterium tuberculosis (TB). Other infections encountered in these genetically determined defects of host defense include intracellular pathogens other than mycobacteria, such as Salmonella species, Listeria, Leishmania, Candida (chronic mucocutaneous candidiasis), fungi (histoplasmosis, paracoccidioidomycosis, coccidioidomycosis), and viruses (cytomegalovirus virus [CMV], human herpesvirus 8 (HHV8), pseudorabies virus 3 [PRV3], respiratory syncytial virus [RSV], and varicella-zoster virus [VZV]). Common to all the infections seen in MSMD are defects in the interferon gamma (IFN-gamma)-interleukin 12 (IL-12) pathway and/or supporting accessory pathways (figure 1). This topic reviews the pathogenesis, typical presentation, diagnosis, and general management of MSMD. Specific forms of MSMD are reviewed separately. (See "Mendelian susceptibility to mycobacterial diseases: Specific defects".)
Host defense against pathogenic (M. tuberculosis [TB]) and nontuberculous (atypical) mycobacteria (M. fortuitum, M. chelonae, M. abscessus, M. avium complex, M. kansasii, M. simiae, and M. marinum), as well as salmonellae, depends heavily upon the functional integrity of mononuclear phagocytes and their interaction with T cells. Interferon gamma (IFN-gamma), a pleiotropic T helper cell type 1 (Th1)-type cytokine, is a principal factor in the elimination of both TB and the nontuberculous group of mycobacteria (NTM) . It is also essential in the control of certain bacterial, parasitic, and viral infections [3-9]. (See "Pathogenesis of nontuberculous mycobacterial infections".)
Macrophages infected with mycobacteria produce the cytokine interleukin 12 (IL-12, which is a heterodimer of IL-12 p40 plus IL-12 p35) . IL-12 stimulates T cells and natural killer (NK) cells via its heterodimeric receptor (IL-12Rbeta1 plus IL-12Rbeta2). In response to stimulation with IL-12, activated T cells and NK cells produce IFN-gamma (figure 1). IFN-gamma binds to its receptor, IFN-gamma-R1, with high affinity, leading to receptor dimerization. This is followed by aggregation of two accessory chains (IFN-gamma-R2) with the receptor complex. IFN-gamma-R2 is required for signal transduction.
Transphosphorylation of Janus kinase 1 and 2 (JAK1 and JAK2), the Janus kinases that are constitutively associated with IFN-gamma-R1 and IFN-gamma-R2 respectively, occurs next . The subsequent signaling event is the tyrosine phosphorylation of the latent cytosolic transcription factor signal transducer and activator of transcription 1 (STAT1), which is followed by homodimerization and translocation of STAT1 to the nucleus as a complex (figure 2).
This initiates the transcription of IFN-gamma-regulated genes [12,13]. One of the results of IFN-gamma activation on phagocytes is the production of tumor necrosis factor alpha (TNF-alpha). In addition, there is further upregulation of IL-12 production. At this point, IFN-gamma also promotes mycobacterial killing, for which the mechanism remains unknown.To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008; 122:1043.
- Stenger S, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999; 2:89.
- Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 1998; 178:1095.
- Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941.
- Lamhamedi S, Jouanguy E, Altare F, et al. Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review). Int J Mol Med 1998; 1:415.
- Altare F, Jouanguy E, Lamhamedi-Cherradi S, et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. Am J Hum Genet 1998; 62:723.
- Altare F, Jouanguy E, Lamhamedi S, et al. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998; 10:413.
- Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999; 27:1368.
- Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr 1999; 135:640.
- Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181:1615.
- Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415.
- Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992; 258:1808.
- Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993; 261:1744.
- Holland SM, Pierce VM, Shailam R, et al. Case 28-2017. A 13-Month-Old Girl with Pneumonia and a 33-Year-Old Woman with Hip Pain. N Engl J Med 2017; 377:1077.
- Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364:2113.
- Wang LH, Yen CL, Chang TC, et al. Impact of molecular diagnosis on treating Mendelian susceptibility to mycobacterial diseases. J Microbiol Immunol Infect 2012; 45:411.
- Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005; 175:4769.
- Browne SK, Holland SM. Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol 2010; 10:534.
- Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.
- Lee WI, Huang JL, Wu TS, et al. Patients with inhibitory and neutralizing auto-antibodies to interferon-γ resemble the sporadic adult-onset phenotype of Mendelian Susceptibility to Mycobacterial Disease (MSMD) lacking Bacille Calmette-Guerin (BCG)-induced diseases. Immunobiology 2013; 218:762.
- Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 2004; 38:e10.
- Höflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004; 103:673.
- Holland SM. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000; 2:1579.
- Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47.
- Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25:545.